Merus (MRUS) Coverage Initiated by Analysts at Guggenheim

Stock analysts at Guggenheim started coverage on shares of Merus (NASDAQ:MRUS) in a research note issued on Friday, April 12th, MarketBeat Ratings reports. The firm set a “buy” rating and a $25.00 price target on the biotechnology company’s stock. Guggenheim’s price target would indicate a potential upside of 68.92% from the stock’s previous close.

A number of other research analysts also recently commented on MRUS. BidaskClub raised Merus from a “strong sell” rating to a “sell” rating in a report on Wednesday, January 9th. Royal Bank of Canada upgraded Merus from a “sector perform” rating to an “outperform” rating and increased their price target for the stock from $18.00 to $23.00 in a research report on Wednesday, April 3rd. Zacks Investment Research cut Merus from a “buy” rating to a “hold” rating in a research report on Wednesday, March 27th. Berenberg Bank began coverage on Merus in a research report on Wednesday, March 27th. They set a “buy” rating and a $35.00 price target on the stock. Finally, ValuEngine upgraded Merus from a “sell” rating to a “hold” rating in a research report on Wednesday, March 6th. Four research analysts have rated the stock with a hold rating and four have given a buy rating to the stock. The company presently has a consensus rating of “Buy” and an average target price of $23.00.

Shares of NASDAQ MRUS traded down $0.67 on Friday, hitting $14.80. The company had a trading volume of 15,314 shares, compared to its average volume of 31,973. The company has a market capitalization of $336.72 million, a price-to-earnings ratio of -8.04 and a beta of -0.05. Merus has a 12-month low of $11.00 and a 12-month high of $26.74.

A number of institutional investors and hedge funds have recently bought and sold shares of MRUS. Artal Group S.A. acquired a new position in shares of Merus during the 4th quarter valued at $2,886,000. JPMorgan Chase & Co. increased its position in shares of Merus by 33.8% during the 3rd quarter. JPMorgan Chase & Co. now owns 17,723 shares of the biotechnology company’s stock valued at $350,000 after purchasing an additional 4,476 shares during the period. Aquilo Capital Management LLC increased its position in shares of Merus by 3.6% during the 3rd quarter. Aquilo Capital Management LLC now owns 1,295,713 shares of the biotechnology company’s stock valued at $25,577,000 after purchasing an additional 44,799 shares during the period. Morgan Stanley increased its position in shares of Merus by 74.3% during the 3rd quarter. Morgan Stanley now owns 71,643 shares of the biotechnology company’s stock valued at $1,415,000 after purchasing an additional 30,538 shares during the period. Finally, Squarepoint Ops LLC increased its position in shares of Merus by 10.3% during the 4th quarter. Squarepoint Ops LLC now owns 11,800 shares of the biotechnology company’s stock valued at $165,000 after purchasing an additional 1,100 shares during the period. Hedge funds and other institutional investors own 53.06% of the company’s stock.

Merus Company Profile

Merus N.V., a clinical-stage immuno-oncology company, engages in developing bispecific antibody therapeutics. Its bispecific antibody candidate pipeline includes MCLA-128, which is in a Phase II clinical trial for the treatment of patients with metastatic breast cancer; and Phase I/II study for treating gastric, ovarian, endometrial, and non-small cell lung cancers.

Further Reading: Economic Reports

Analyst Recommendations for Merus (NASDAQ:MRUS)

Receive News & Ratings for Merus Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Merus and related companies with MarketBeat.com's FREE daily email newsletter.